Newsletters arkiv förslag

In this issue: Bayer v Sandoz, STADA, Teva, Glenmark, and Viatris over rivaroxaban products STADA and Sandoz v Takeda over the validity of lisdexamfetamine SPC and lisdexamfetamine product

In this issue: Bayer v Sandoz, STADA, Teva, Glenmark, and Viatris over rivaroxaban products STADA and Sandoz v Takeda over the validity of lisdexamfetamine SPC and lisdexamfetamine product

In this issue: Bayer v Sandoz, STADA, Teva, Glenmark, and Viatris over rivaroxaban products STADA and Sandoz v Takeda over the validity of lisdexamfetamine SPC and lisdexamfetamine product

The Swedish pharma and life sciences litigation newsletter SEPTEMBER 2024 IN THIS ISSUE Pharma: Bayer v Sandoz, STADA, Teva, Glenmark, and Viatris over rivaroxaban products Pharma: Sandoz and STADA v Takeda over lisdexamfetamine product and the…

JANUARY 2024 The Swedish pharma and life sciences litigation newsletter IN THIS ISSUE Pharma: Biogen v Sandoz, Viatris, and Neuraxpharm over dimethyl fumarate products Pharma: Novartis v Zentiva, Glenmark, Mylan, and Teva over fingolimod products MedTech:…